{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:41:57Z","timestamp":1785894117962,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.010","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:43:31Z","timestamp":1663735411000},"page":"1336-1355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Population Pharmacokinetics and Exposure\u2013Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-3801","authenticated-orcid":false,"given":"Omoniyi J.","family":"Adedokun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gasink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.010_bib0001","series-title":"INN-Ustekinumab Prescribing Information","year":"2022"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bcp.14971","article-title":"Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease","volume":"88","author":"Wang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0004","unstructured":"European Medicines Agency. Assessment report: Stelara. 15 September 2016. Accessed April 19, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/stelara-h-c-000958-x-0049-g-epar-assessment-report-extension_en.pdf."},{"key":"10.1016\/j.clinthera.2022.08.010_bib0005","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0006","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5414\/CPP48830","article-title":"Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis","volume":"48","author":"Zhu","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0007","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/jcph.1582","article-title":"Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis","volume":"60","author":"Xu","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0008","unstructured":"Stelara. Prescribing Information. Janssen; 2020. Accessed April 21, 2021. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf."},{"key":"10.1016\/j.clinthera.2022.08.010_bib0009","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1011579109640","article-title":"Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test","volume":"28","author":"Kowalski","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0013","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","article-title":"Ustekinumab in pediatric patients with moderately to severely active Crohn's disease pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study","volume":"15","author":"Rosh","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0014","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","article-title":"Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study","volume":"19","author":"Adedokun","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0016","unstructured":"Humira. Prescribing Information. AbbVie; 2021 Accessed April 21, 2021. https:\/\/www.rxabbvie.com\/pdf\/HUMIRA.pdf."},{"key":"10.1016\/j.clinthera.2022.08.010_bib0017","unstructured":"Entyvio. Prescribing Information. Takeda; 2021. Accessed April 21, 2021. https:\/\/general.takedapharm.com\/ENTYVIOPI."},{"key":"10.1016\/j.clinthera.2022.08.010_bib0018","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0020","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0021","series-title":"Summary of Product Characteristics","year":"2013"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0022","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1185\/030079907X182112","article-title":"A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12\/23 monoclonal antibody in subjects with plaque psoriasis","volume":"23","author":"Gottlieb","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0023","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","article-title":"A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis","volume":"123","author":"Kauffman","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0024","unstructured":"United States Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review for ustekinumab single use liquid in vial, 45 mg\/0.5 mL and 90 mg\/1.0 mL. 2009. Accessed April 21, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125261s000_ClinPharmR.pdf."},{"key":"10.1016\/j.clinthera.2022.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40262-018-0704-z","article-title":"Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn's disease: analyses of phase I and II trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0027","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgs.2016.17","article-title":"Using markers in IBD to predict disease and treatment outcomes: rationale and a review of current status","volume":"3","author":"Lichtenstein","year":"2016","journal-title":"Am J Gastroenterol Suppl"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0029","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/00365521.2021.1906315","article-title":"A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland","volume":"56","author":"Sipponen","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40261-013-0072-2","article-title":"Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two phase 1 studies","volume":"33","author":"Zhu","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0032","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jcph.231","article-title":"A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed?","volume":"54","author":"Chiba","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0033","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/jcph.1473","article-title":"Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis","volume":"59","author":"Khatri","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0034","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5217\/ir.2019.09167","article-title":"Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease","volume":"19","author":"Okamoto","year":"2021","journal-title":"Intest Res"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0036","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bcp.12313","article-title":"Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis","volume":"78","author":"Ternant","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0037","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0038","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.08.010_bib0039","unstructured":"European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. October 7, 2018. Accessed April 21, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:48Z","timestamp":1758963468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002922"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetics and Exposure\u2013Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}